Do Wall Street Analysts Like Medtronic Stock?
Analysts covering Medtronic (MDT) expect fiscal-year EPS for the year ending April 2027 to rise 7.4% to $5.94. The stock has beaten consensus EPS in each of the last four quarters. Of 29 analysts, consensus is “Moderate Buy” with 15 “Strong Buy” ratings. UBS upgraded MDT to “Buy” with a $100 target; mean target is $96.81 and Street-high is $120.
How this was made
The 30-second read
Why it matters
This is primarily a sentiment and positioning update for MDT, reflecting how analysts are framing the next fiscal year EPS growth and recent earnings beats.
Market read
Traders may use the upgrade and target dispersion as a short-term sentiment input, but there is no new operational or financial disclosure.
What to watch
The piece does not detail the upgrade thesis or any updated fundamentals, so traders may overestimate the durability of the bullish targets.
Background
The article summarizes sell-side consensus for Medtronic and highlights a recent UBS upgrade and price targets.
Ticker impact
UBS upgraded Medtronic to a Buy and set a $100 price target, with the article citing upside versus current levels.
Near-term support from upgrade-driven flows is plausible, but the move is likely sentiment-driven rather than fundamental.
The article provides concrete rating and target changes (UBS upgrade, Street-high target), but no new company fundamentals like earnings, guidance, trials, or contracts.
Market effects
Could modestly lift sentiment across medical devices, but the article is single-name analyst-target focused.
No clear regional spillover beyond US-listed MDT coverage.
Limited, since the catalyst is an analyst action rather than a global regulatory or product event.
Counterpoint
Analyst upgrades can fade quickly if they are not tied to new earnings, guidance, or trial/product catalysts.
Key entities
- companyMedtronic
Subject of the article, with consensus rating, EPS expectations, and a UBS upgrade with a $100 target.



